Guinea

Start of program: 2014

Country key figures:

13.13 million inhabitants¹

30,770 COVID-19 cases²

ALIMA’s key figures:

2,330 patients monitored as part of the PREVAC-UP

4,399 suspected and confirmed COVID-19 patients cared for

Areas of intervention:

Research and innovation

Outbreak response

Maternal health

Country context

In Guinea, maternal and infant mortality is still very high. Moreover, the Guinean health system was particularly affected by the Ebola epidemic in 2014³.

Much of the Guinean population has inadequate access to medical facilities. The country’s health system has been further strained by various outbreaks, including the COVID-19 pandemic.

ALIMA's impact - our fieldwork

Implementation of research projects against Ebola

Two research projects continued this year:

The PREVAC (Partnership for Research on Ebola Vaccination) phase II trial, which started in 2015, to identify an effective Ebola vaccine. In 2020, over 2,300 enrolled participants continued to be monitored, as part of a longer-term study, called PREVAC-UP.
The Ebovac III project, a trial that aims to evaluate the efficacy of an Ebola vaccine in infants younger than one year.

Implementation of the AIRE (Improving the Identification of Respiratory Distress in Children) Project

The implementation of the AIRE (Improving the Identification of Respiratory Distress in Children) project, which is funded by Unitaid, began in 2020. The AIRE teams collected information and established partnerships that are essential to the continuation of the project over the next few years.

The project also adapted to the pandemic with “COVID-AIRE,” enabling the implementation of 30 patient triage circuits, the donation of 30 IPC triage kits, 34 pulse oximeters and 10 oxygen concentrators.